The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-AKR1C3 antibody (ab27491)
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
17 beta HSD 5
17 beta hydroxysteroid dehydrogenase type 5
17-beta-hydroxysteroid dehydrogenase type 5
3 alpha hydroxysteroid dehydrogenase type II
3-alpha-HSD type 2
3-alpha-HSD type II
3-alpha-HSD type II, brain
3-alpha-hydroxysteroid dehydrogenase type 2
Aldo keto reductase family 1 member C3
Aldo-keto reductase family 1 member C3
Chlordecone reductase homolog HAKRb
Dihydrodiol dehydrogenase 3
Dihydrodiol dehydrogenase type I
Dihydrodiol dehydrogenase X
Prostaglandin F synthase
Testosterone 17-beta-dehydrogenase 5
Type IIb 3 alpha hydroxysteroid dehydrogenase
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. The dominant HSD in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate.